Phase 1 Trial of IMAB027 in Patients With Recurrent Advanced Ovarian Cancer (OVAR)
NCT02054351
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
42
Enrollment
INDUSTRY
Sponsor class
Conditions
Ovarian Cancer
Interventions
DRUG:
IMAB027
Sponsor
Ganymed Pharmaceuticals GmbH